Mountain Valley MD updates on recent key initiatives, including award of 'cornerstone' patent

Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCMKTS:MVMD) has updated on the company’s recent key strategic achievements, including news the United States Patent Trademark Office (USPTO) has approved a “cornerstone” patent related to the company’s solubilization technology.

In a wide-ranging update, the biotech and life sciences company said the patent related to its invention of the Water Dissolvable Macrocyclic Lactone Cyclodextrin Complexes.

Dennis Hancock, Mountain Valley MD CEO, said the patent would allow the group “to move forward in securing the global protections necessary across many human and animal health applications without competitive interference”.

READ: Mountain Valley MD looking to eradicate needles with its patented Quicksome oral drug delivery technology

Mountain Valley MD is focused on implementing its patented Quicksome oral drug formulation and delivery technologies. In addition, the firm revealed that its Quicksol trademark application has now passed through the examination phase at the US Trademark Office and was currently in its final 30 day “external” review process.

Elsewhere, across the business, the company highlighted that its production partner has reported positive results from the initial manufacturing assessment of Ivectosol, which means Mountain Valley MD can now supply the quantities necessary for planned oncology and coronavirus (COVID-19) phased human trials.

The firm also highlighted its two-year collaborative research agreement with the US Food and Drug Administration (FDA), which will govern its cold chain project, and it will now aim for a detailed review session with the regulator.

Also, in partnership with the Tulane University School of Medicine in New Orleans, Mountain Valley MD said it had carried out a study comparing an existing Alhydrogel adjuvant to the firm’s invented stable nano-particulate adjuvant by both intramuscular injection and intradermal injection immunization.

In husbandry, the firm has kicked off animal trials to validate the superiority of its injectable solubilized Ivermectin technology, Ivectosol 1%, versus current commercially available forms to treat a broad category of animal parasites, while in tuberculosis research, it has successfully applied its Quicksol solubilization science to a macrocyclic lactone drug, Selamectin.

Finally, in cannabis, Mountain Valley MD said it was currently working through CBD and THC product formulations for a North American cannabis company. If successful, it anticipates entering into a license agreement with the partner and commencing retail production.

The firm’s Quicksome technology uses advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally.

The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy.

Contact the writer at [email protected]

Story by ProactiveInvestors